Silverback Therapeutics, Inc.
SBTX
Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to... Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immune response through the precise activation of TLR8 within the liver. The company was founded in 2016 and maintains its principal offices in Seattle, Washington.